Changes of PACAP level in cerebrospinal fluid and plasma of patients with severe traumatic brain injury

Peptides

Volumn 60, Issue , 2014, Pages 18-22

  Bukovics, Peter ^a   Czeiter, Endre ^a   Amrein, Krisztina ^a   Kovacs, Noemi ^a   Pal, Jozsef ^a   Tamas, Andrea ^a   Bagoly, Terez ^a   Helyes, Zsuzsanna ^a   Buki, Andras ^a   Reglodi, Dora ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Endogenous PACAP; Neuroprotective; Plasma; Traumatic brain injury

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN DAMAGE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLASGOW COMA SCALE; HUMAN; MALE; MORTALITY; PLASMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TIME OF DEATH; TRAUMATIC BRAIN INJURY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; ADOLESCENT; BLOOD; BRAIN INJURY; INJURY SCALE; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN INJURIES; FEMALE; HUMANS; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; YOUNG ADULT;

EID: 84906083039     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2014.07.001     Document Type: Article

References (49)

1. B. Armstrong, C. Abad, S. Chhith, G. Cheung-Lau, O. Hajji, and H. Nobuta et al. Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide Neuroscience 151 2008 63 73
2. T. Atlasz, N. Babai, P. Kiss, D. Reglodi, A. Tamás, and K. Szabadfi et al. Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats Gen Comp Endocrinol 153 2007 108 114
3. N. Babai, T. Atlasz, A. Tamás, D. Reglödi, G. Tóth, and P. Kiss et al. Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retinal degeneration Neurotox Res 8 2005 227 233
4. W.A. Banks, A.J. Kastin, G. Komaki, and A. Arimura Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier J Pharmacol Exp Ther 267 1993 690 696
5. M. Beal, T. Palomo, R. Kostrzewa, and T. Archer Neuroprotective and neurorestorative strategies for neuronal injury Neurotox Res 2 2000 71 84
6. B.J. Blyth, A. Farhavar, C. Gee, B. Hawthorn, H. He, and A. Nayak et al. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury J Neurotrauma 26 2009 1497 1507
7. H. Bramlett, and W. Dietrich Pathophysiology of cerebral ischemia and brain trauma: similarities and differences J Cereb Blood Flow Metab 24 2004 133 150
8. W. Chen, and S. Tzeng Pituitary adenylate cyclase-activating polypeptide prevents cell death in the spinal cord with traumatic injury Neurosci Lett 384 2005 117 121
9. A. Chodobski, B.J. Zink, and J. Szmydynger-Chodobska Blood-brain barrier pathophysiology in traumatic brain injury Transl Stroke Res 2 2011 492 516
10. M. Das, S. Mohapatra, and S.S. Mohapatra New perspectives on central and peripheral immune responses to acute traumatic brain injury J Neuroinflammation 9 2012 12
11. P.K. Dash, J.B. Redell, G. Hergenroeder, J. Zhao, G.L. Clifton, and A. Moore Serum ceruloplasmin and copper are early biomarkers for traumatic brain injury-associated elevated intracranial pressure J Neurosci Res 88 2010 1719 1726
12. M. Delgado, C. Abad, C. Martinez, M.G. Juarranz, J. Leceta, and D. Ganea et al. PACAP in immunity and inflammation Ann N Y Acad Sci 992 2003 141 157
13. M. Delgado, C. Martinez, D. Pozo, J.R. Calvo, J. Leceta, and D. Ganea et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6 J Immunol 162 1999 1200 1205
14. R. Diaz-Arrastia, K.K. Wang, L. Papa, M.D. Sorani, J.K. Yue, and A.M. Puccio et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein J Neurotrauma 31 2014 19 25
15. R. Dow, J. Bennie, and G. Fink Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat J Endocrinol 142 1994 R1 R4
16. O. Farkas, A. Tamas, A. Zsombok, D. Reglodi, J. Pal, and A. Buki et al. Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury Regul Pept 123 2004 69 75
17. S. Feng, X. Kong, S. Guo, P. Wang, L. Li, and J. Zhong et al. Treatment of spinal cord injury with co-grafts of genetically modified Schwann cells and fetal spinal cord cell suspension in the rat Neurotox Res 7 2005 169 177
18. J. Garcia de Yebenes, J. Yebenes, and M. Mena Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease Neurotox Res 2 2000 115 137
19. M. Gerlach, K. Double, M. Youdim, and P. Riederer Strategies for the protection of dopaminergic neurons against neurotoxicity Neurotox Res 2 2000 99 114
20. Z. Helyes, G. Pozsgai, R. Börzsei, J. Németh, T. Bagoly, and L. Márk et al. Inhibitory effect of PACAP-38 on acute neurogenic and non-neurogenic inflammatory processes in the rat Peptides 28 2007 1847 1855
21. M. Katahira, K. Yone, Y. Arishima, T. Nagamine, S. Komiya, and S. Iwata et al. The neuroprotective effects of PACAP on spinal cord injury (SCI) in rats Regul Pept 115 2003 49
22. W. Kim, Y. Kan, D. Ganea, R. Hart, I. Gozes, and G. Jonakait Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway J Neurosci 20 2000 3622 3630
23. J. Langlois, W. Rutland-Brown, and K. Thomas Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths 2006 Centers for Disease Control and Prevention, National Center for Injury Prevention and Control Atlanta, GA
24. M. Li, J.L. Maderdrut, J.J.L. Lertora, and V. Batuman Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study Peptides 28 2007 1891 1895
25. J. Lu, S.J. Goh, P.Y.L. Tng, Y.Y. Deng, E.A. Ling, and S. Moochhala Systemic inflammatory response following acute traumatic brain injury Front Biosci, Landmark 14 2009 3795 3813
26. C. Martinez, A. Arranz, Y. Juarranz, C. Abad, M. Garcia-Gomez, and F. Rosignoli et al. PAC1 receptor: emerging target for septic shock therapy Ann N Y Acad Sci 1070 2006 405 410
27. A. Miyata, A. Arimura, R. Dahl, N. Minamino, A. Uehara, and L. Jiang et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells Biochem Biophys Res Commun 164 1989 567 574
28. C.J.L. Murray, and A.D. Lopez Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study Lancet 349 1997 1498 1504
29. J. Németh, D. Reglödi, G. Pozsgai, A. Szabó, K. Elekes, and E. Pintér et al. Effect of pituitary adenylate cyclase activating polypeptide-38 on sensory neuropeptide release and neurogenic inflammation in rats and mice Neuroscience 143 2006 223 230
30. B. Racz, D. Reglodi, P. Kiss, N. Babai, T. Atlasz, and R. Gabriel et al. In vivo neuroprotection by PACAP in excitotoxic retinal injury: review of effects on retinal morphology and apoptotic signal transduction Int J Neuroprot Neurodeg 2 2006 80 85
31. D. Reglodi, A. Tamas, A. Lubics, L. Szalontay, A. Zsombok, and O. Farkas et al. Recent results on the neuroprotective effects of PACAP in rat models of focal cerebral ischemia, Parkinson's disease and traumatic brain injury Neurotox Res 8 2005 317
32. D. Reglodi, A. Tamás, A. Lubics, L. Szalontay, and I. Lengvári Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats Regul Pept 123 2004 85 94
33. D. Reglodi, A. Tamás, A. Somogyvári-Vigh, Z. Szántó, E. Kertes, and L. Lénárd et al. Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia Peptides 23 2002 2227 2234
34. D. Reglödi, A. Lubics, P. Kiss, I. Lengvári, B. Gaszner, and G. Tóth et al. Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats Neuropeptides 40 2006 265 274
35. B. Rácz, F.J. Gallyas, P. Kiss, G. Tóth, O. Hegyi, and B. Gasz et al. The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involve inhibition of proapoptotic signaling pathways Regul Pept 137 2006 20 26
36. M.M. Saw, J. Chamberlain, M. Barr, M.P. Morgan, J.R. Burnett, and K.M. Ho Differential disruption of blood-brain barrier in severe traumatic brain injury Neurocrit Care 20 2014 209 216
37. J. Segura-Aguilar, and R. Kostrzewa Neurotoxins and neurotoxicity mechanisms. An overview Neurotox Res 10 2006 263 287
38. S. Shioda, H. Ohtaki, T. Nakamachi, K. Dohi, J. Watanabe, and S. Nakajo et al. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment Ann NY Acad Sci 1070 2006 550 560
39. S. Shioda, H. Ozawa, K. Dohi, H. Mizushima, K. Matsumoto, and S. Nakajo et al. PACAP protects hippocampal neurons against apoptosis: involvement of JNK/SAPK signaling pathway Ann NY Acad Sci 865 1998 111 117
40. D. Shlosberg, M. Benifla, D. Kaufer, and A. Friedman Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury Nat Rev Neurol 6 2010 393 403
41. Y. Skoglösa, A. Lewén, N. Takei, L. Hillered, and D. Lindholm Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type 1 after traumatic brain injury: comparison with brain-derived neurotrophic factor and the induction of neuronal cell death Neuroscience 90 1999 235 247
42. A. Somogyvári-Vigh, and D. Reglodi Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide Curr Pharm Des 10 2004 2861 2889
43. A. Tamas, D. Reglodi, O. Farkas, E. Kovesdi, J. Pal, and J.T. Povlishock et al. Effect of PACAP in central and peripheral nerve injuries Int J Mol Sci 13 2012 8430 8448
44. J.W. Tams, A.H. Johnsen, and J. Fahrenkrug Identification of pituitary adenylate cyclase-activating polypeptide 1-38-binding factor in human plasma, as ceruloplasmin Biochem J 341 1999 271 276
45. A. Tamás, A. Lubics, I. Lengvári, and D. Reglódi Protective effects of PACAP in excitotoxic striatal lesion Ann NY Acad Sci 1070 2006 570 574
46. A. Tamás, A. Zsombok, O. Farkas, D. Reglödi, J. Pál, and A. Büki et al. Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats J Neurotrauma 23 2006 686 695
47. F.K.H. van Landeghem, T. Weiss, M. Oehmichen, and A. von Deimling Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans Acta Neuropathol 113 2007 683 693
48. D. Vaudry, A. Falluel-Morel, S. Bourgault, M. Basille, D. Burel, and O. Wurtz et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery Pharmacol Rev 61 2009 283 357
49. D. Vaudry, B. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions Pharmacol Rev 52 2000 269 324